Penelitian longitudinal prospektif analitik untuk menilai ketepatan prediksi timbulnya penyakit trofoblas ganas melalui sistem penilaian prognosis mola hidatidosa yang dikembangkan oleh NETDC (New England Trophoblast Disease Center) 
Gestational trophoblastic tumors (GTTs) are rare but highly curable tumors arising from the products of conception in the uterus. The prognosis for cure of patients with GTTs is good even when the disease has spread to distant organs, especially when only the lungs are involved. The probability of cure depends on the histologic type (mole, invasive mole, or choriocarcinoma), the extent of spread of the disease, the level of the human chorionic gonadotropin (hCG) titer, the duration of disease from initial pregnancy event to start of treatment, the specific sites of metastases, the nature of antecedent pregnancy, and the extent of prior treatment. Selection of treatment on these factors plus the patient's desire for future pregnancies. Human chorionic gonadotropin, produced normally during pregnancy, is abnormally elevated in the blood and urine of patients with this group of diseases and is a sensitive marker to indicate the presence or absence of disease before, during and after treatment. 1, 2 The most common antecedent pregnancy is that of a hydatidiform mole, usually a genetic disorder of pregnancy in which only placental-like tissue is present. The patient will present with abnormal bleeding from onset of pregnancy and may have a uterus which is much larger than expected. Sonography is the preferred method of diagnosis, and suction curettage is the preferred method of evacuation. Of most importance is careful follow-up with serum beta HCG (βhCG) weekly until less than 100 mIU/mL and then every two weeks. The patient should have a careful pelvic examination every other week and a chest x-ray every 4-6 weeks. Once the titer of serum βhCG has fallen to normal levels, these two examinations need no longer be done; however, βhCG titers need to be repeated every 2 weeks for 3 months, then monthly for 3 months, then every 2 months for 6 months, then every 6 months for 3 years. Each patient should be counseled in the use of a reliable birth control method. Any patient who develops an increasing level of serum βhCG, a plateau of the βhCG over 3 weeks, or persistent elevation of βhCG after 16 weeks of follow-up should be considered as having gestational trophoblastic tumor and should undergo the appropriate work-up and treatment. Similarly, any patient who develops metastatic disease during follow-up should be staged and undergo treatment. 2, 3 Various classification systems for gestational trophoblastic tumors (GTTs) have been applied. An anatomical staging system has been adopted by FIGO (International Federation of Gynecology and Obstetrics). In addition, the NETDC (New England Trophoblastic Diseases Centre) has proposed a prognostic scoring system for the determination of therapy. There has, however, been a lack of uniformity in the use of these systems.
MATERIAL AND METHODS
This study includes patients with hydatidiform mole diagnosed in Mohammad Hoesin Hospital Palembang, from January 2001 to December 2002. The patients divided into high and low risk for NETDC prognostic score with determining factors were type of hydatidiform mole, uterine enlargement, lutein cyst, age and abcent or present factors correlated with hydatidiform mole. The patients with hydatidiform mole included in this study were those evacuated at Dr. Moh. Hoesin Hospital. Before that the patients will take the blood sample for βHCG serum examination and other clinical and laboratory examination to determine high and low risk. The patient will be closely follow up for a year to observe malignancy after hydatidifom mole evacuated.
We computed relative risk as estimators of high and low risk, together with their 95% approximate confidence interval. A  2 test was used to compare the distribution of various patient characteristics in the two risk score group. Logistic regresion will be determine what is the factor was influence to malignancy. A significance level of .05 was chosen. However, because adjustment for most covariates and important prognostic score in NETDC score, we present estimates high and low risk for occur malignancy after evacuated hydatidiform mole. The data were analyzed using the program package SPSS 11.5 for windows. Based on the last menstruation period, pregnancy length of the high risk group was 12.77 ± 4.07 weeks ; this was a little bit higher than that of the low risk group (14.50 ± 2.35 weeks)(ρ > 0.05). In contrast, in fundal height, it showed the following data (19.53 ± 3.9 weeks for the high risk group and 16.90 ± 3.81 weeks for the low risk group) (ρ < 0.05). In terms of uterine fundal height, the average pregnancy length was higher than the first day of the last menstruation period (ρ < 0.05).
The number of patients and their husbands having O blood group was 52 % and 38.5 % became gestational trophoblastic tumor (ρ > 0.05). Eight patients (33.3 %) having anemia became gestational trophoblastic tumor, and nine patients (34.6%) had no anemia. Nine patients (10%) showed positive urine proteins, and the rest showed the negative ones. Three patients (6%) showed positive acetone urine and 47 (94%) did not. There were no correlation between blood group, anemia, protein urine, or acetone urine and gestational trophoblastic tumor (ρ > 0.05). Average T3 composition was 2.22 ± 1.11 ng/ml and that of T4 was 18.87 ± 6.95 ug/dl. T3 and T4 contents showed differences in the high risk and low risk groups (ρ < 0.05). There were no significant correlation between Wayne index and the risk grouping (ρ > 0.05). The Index showing hyperthyroid (57.1%) indicated that they would suffer gestational trophoblastic tumor (ρ < 0.05). The Kariadi index showed that 11 patients (55%) suffering thyrotoxycosis and six patients (20%) having euthyroid would undergo gestational trophoblastic tumor (ρ < 0.05) ( Table 2) . Pathologically, all high risk patients suffered complete hydatidiform mole, 34.7% of them experienced gestational trophoblastic tumor, and only one of them had partial hydatidiform mole (ρ > 0.05). As for  hCG, high risk patients showed an average of 56,863.50 ± 53,722.77 mIU/ml and the low risk ones 16,793.09 ± 25,181.70 mIU/ml and they significantly turned into sufferers of gestational trophoblastic tumor (ρ < 0.05). Fifty eight percent of the patients with a ß hCG concentration of over 50,000 mIU/ml and 21.2% with that of less than 50,000 mIU/ml suffered gestational trophoblastic tumor (ρ < 0.05). NETDC prognostic scores obtained through a univariate regression analysis indicated that only the variable of ß hCG serum concentration and medical factors had significant traces of the occurrence of gestational trophoblastic tumor (ρ < 0.05). A further analysis showed the dominance of  hCG only (ρ = 0.02). In general, the variables above had an influence in the occurrence of gestational trophoblastic tumor (ρ = 0.032).
Based the NETDC prognostic scores, it was found that 50 % of hydatidiform mole occurred to the high risk group (a score of ≥ 4) and 10% to the low risk group (a score of < 4) that led to gestational trophoblastic tumor (ρ < 0.05). The high risk group suffered nine times higher than the low risk group (confidence interval: 1.769 -45.786) ( Table 3) . Average time intervals between the diagnose of hydatidiform mole and gestational trophoblastic tumor was 10.00 ± 7.28 months. The interval for the high risk group was 6.00 ± 2.83 months and the low risk group 10.53 ± 7.57 months (ρ = 0.426).
Within the 12-month observation, the high risk group showed a less survival rate than the low risk group (40% to 50%) but in the fifth months, the high risk group showed a higher survival rate (86.67% to 50%). This difference cannot be statistically proved (ρ = 0.710). (Figure 1 ). 
DISCUSSION
Determination of hCG concentration with positive reaction pregnancy test was not pathognomonic. Hydatidiform mole was suspected when the pregnancy test solution was positive at 1/200. The hCG concentration was more frequently used for a prognostic factor. A hCG concentration of more than 100,000 mIU/ml is used as one of the high risk criteria that indicates the presence of post-hydatidiform mole. 4, 5, 6, 8 Maternal age is constantly identified as a high risk factor. Presence of a specific age is depicted in the J curve: young age is the most dominant and the number of patients over 40 years is dramatically high. 5, 6, 7 This research shows the most dominant group age falls between 20 and 35, 20 is the most frequently-tabulated age, namely 7 patients. Many references state that the group range in which hydatidiform mole occurs generally falls at the extreme reproductive age. Its distribution is usually depicted as the J curve. However, this research results in a rather different distribution; it is depicted in the parabola curve.
It was found that hydatidiform mole occurred most in the 2-5 parity group (48%). Only 4% occurred in the 6 or over parity group. In general, this distribution showed an enlarging curve that concurrently increased along with the increase in parity but suddenly lowered down as it reached at the 5 parity. 9 The data shows that the length of pregnancy examined based on the fundus uteri height was bigger than that based on the last menstruation period. This fits the description of hydatidiform mole in general; 50% of hydatidiform mole uterine is much larger than the real length of pregnancy. The difference in the high risk group is big enough (6.76 weeks) whereas the one in the low risk group is small (2.40 weeks). These two differences are statistically significant (ρ < 0.05) Forty to fifty percent of the patients with complete hydatidiform mole showed an enlargement of uterus more than 4 weeks, which differed from that of the last menstruation period. [10] [11] [12] [13] Uterine enlargement was caused by the expansion of hyperplasia tropoblast and the bleeding of uterine cavity. Although this uterine enlargement -compared to the real length of pregnancy -was a regular clinic manifestation, 15% to 40% of the patients originally had a small uterine than gestational age.
Average T 3 concentration in this research is 2.22 ± 1.11 ng/ml whereas that of T 4 is 18.87 ± 6.95 ug/ml (normally T 3 range is 0.8 -2 ng/ml, and T 4 range 4 -12 ng/dl). The two values were above the normal ones. Clinical evidence of hyperthyroid presence as an indicator of complete hydatidiform mole was found in 2% to 7% percent of the patients.
14,15 They showed symptoms and signs of enlarging thyroid, tachycardi, febris, and tremor, and critical thyroid sometimes appeared. The evidence that hCG concentration proves as a thyrotropic factor in stimulating the surge of thyrotoxicosis is still a question for further research.
It was found that there was no correlation between the Wayne index value and the grouping of patients with hydatidiform mole (ρ > 0.05). However, the Wayne index indicated the presence of more thyroid in the high risk group (85.7%) than in the low risk group (14.3%). The Kariadi index showed that 60% of hydatidiform mole patients suffered euthyroid and 40% thyrotoxicosis. Sixteen patients (53.3%) with euthyroid and 14 patients (70%) with thyrotoxicosis fell in the high risk criteria. It could be also seen that, based on the Kariadi Index, the number of thyrotoxicosis patients is larger than that of euthyroid ones although this significant difference cannot be proved statistically (ρ > 0.05).
HCG is a glycoprotein hormone that consists of two subtypes:  and ß. The  hCG type is like the glycoprotein pituitary hormone while the other one is unique and different from all other hormones. This hormone is produced by the trophoblast tissue when a patient is pregnant and trophoblast attacks her. A little amount of this hormone is also produced by a certain type of carcinoma tissue. The main function of ß hCG hormone is to increase the progesterone release by corpus luteum of ovarium. This research shows that average ß hCG concentration that happened to the high risk group fell within this range: 56,863.50 ± 53,722.77 mIU/ml and the low risk group: 16,793.09 ± 25,181.70 mIU/ml. In this research, average ß hCG concentration prior to evacuation showed a statistically significant difference and whether or not it developed into gestational trophoblastic tumor (ρ < 0.05). The pre-evacuation ß hCG concentration of hydatidiform mole patients that became gestational trophoblastic tumor was higher. It could also noticed that 58.8% of the patients with ß hCG concentration over 50,000 mIU/ml then suffered gestational trophoblastic tumor. Only 21.2% of the patients showed a ß hCG concentration less than 50,000 mIU/ml.
The analysis of statistical logistic regression showed that the ß hCG serum concentration variable and presence or absence of other medical factors played a role in causing gestational trophoblastic tumor to develop (ρ < 0.05). In general all these variables affected the development of gestational trophoblastic tumor as shown by the ρ value of 0.032. A further analysis showed that only the ß hCG constituted a dominant factor (ρ = 0.02).
The NETDC prognostic scores showed that 50% of high risk hydatidiform mole cases developed into malignancy cases whereas 10% of those of low risk ones developed into the malignancy.
The gestational trophoblastic tumor did not only develop from hydatidiform mole, but also from cases of pregnancies and post-abortus. Several prognostic scores were created as a means of predicting the acuteness of post-hydatidiform mole. Bagshawe and WHO pioneered the development of these prognostic scores. In general, it is agreed that 19% to 30% of high risk hydatidiform mole cases will develop into malignancy cases while that of low risk constitute 5% to 10%. This study shows that the presence of gestational trophoblastic tumor in the high risk group is nine times higher than that of the low risk group. (Confidence interval: 1.769 -45.786).
The average time intervals between the hydatidiform mole diagnosis and the finding of gestational trophoblastic tumor for all patients was 10.00 ± 7.28 months: the average of 6.00 ± 2.83 months for the high risk group and 10.53 ± 7.57 months for the low risk group (ρ = 0.426). It could be seen that the 12-month observation on the high risk group demonstrated a lower survival rate than the low risk group (40% : 50%). 
Summary
Predictive or prognostic score of post-hydatidiform mole based on the high-and low-risk grouping was still high. The malignancy experienced by patients of the high risk group is nine times higher than those of the low risk group. Special effort to detect this malignancy as early as possible and thus reduce the number of the high risk patients is crucial; it will decrease the number of diseases and death caused by complication and/or malignancy.
